Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): An updated meta-analysis

Critical Care

Volumn 23, Issue 1, 2019, Pages

  Yamakawa, Kazuma ^a   Levy, Jerrold H ^b   Iba, Toshiaki ^c  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOMODULIN;

BLOOD CLOTTING DISORDER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; SEPSIS;

BLOOD COAGULATION DISORDERS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS; THROMBOMODULIN;

EID: 85071782071     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-019-2587-2     Document Type: Letter

References (5)

1. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy. JAMA. 2019;321(20):1993-2002.
2. van der Poll T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: another negative sepsis trial? JAMA. 2019;321(20):1978-80.
3. Yamakawa K, Umemura Y, Hayakawa M, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229.
4. Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost. 2019;119(1):56-65.
5. Vincent JL. The coming era of precision medicine for intensive care. Crit Care. 2017;21(Suppl 3):314.